Secure Blockchain Transactions for Electronic Health Records based on an Improved Attribute-Based Signature Scheme (IASS)

Electronic Health Records (EHRs) are entirely controlled by hospitals, not patients, making it difficult to obtain medical advice from individual hospitals. Patients need to keep tabs on their health details and take back control of their medical data. The rapid development of blockchain technology has facilitated large-scale healthcare, including medical records and patient-related data. The technology provides comprehensive and immutable patient records and free access to electronic medical records for providers and treatment portals. To ensure the validity of the blockchain-connected EHR, the Improved Attribute-Based Signature Scheme (IASS) has considerable powers, allowing patients to approve messages based on attributes but not validated. In addition, it avoids the problem of having multiple authorities without a single or central source of trust for generating and distributing patient public/private keys and fits into the blockchain model for distributed data storage. By sharing a secret, pseudo-random activity seed between authorities, the protocol resists collusive attacks by corrupt officials. The technology provides patients with a comprehensive, immutable record and free access to their EHR from providers and treatment portals. To ensure the validity of blockchain-connected EHRs, propose an attribute-based multi-authority signature scheme that authorizes messages based on their attributes without revealing any information

Comparison of Friedewald’s formula, modified Friedewald’s formula and Anandaraja’s formula with direct homogenous serum LDL cholesterol method in CHD patients

Background: Elevated serum Low-Density Lipoprotein Cholesterol (LDL-C) concentration is a well-known atherogenic risk factor with a high predictive value for coronary heart disease. An important aspect of the assessment of coronary heart disease risk for a dyslipidemic subject is the estimation of serum Low-Density Lipoprotein Cholesterol (LDL-C). There are many homogenous assays currently available for the estimation of serum LDL-C. Most clinical laboratories determine LDL-C (mg/dl) by Friedewald’s formula (FF), LD-=(TC)-HDL-C)-(TG/5), Modified Friedewald’s formula (MFF), LDL-C=(TC)-(HDL-C)-(TG/6), Recently Anandaraja and colleagues have derived a new formula for calculating LDL-C, AR-LDL-C=0.9 TC-(0.9 TG/5)-28.Methods: It is cross-sectional study. Lipid profile data was collected from known of CHD patients, who had come for lipid profile investigation to the Central Biochemistry laboratory of ACPM Medical College and hospital. LDL-C estimation was done by direct homogenous assay and also calculated using the Friedewald’s Formula, Modified Friedewald’s Formula and Anandaraja’s Formula for assessing and validity of the LDL cholesterol.Results: From the present study, The LDL-FF, MFW and AR are increased with levels of TGL > 200 mg/dl and decreased level of TC < 200 mg/dl seem to interfere with the estimation of Direct LDL cholesterolConclusions: Authors conclude that, LDL-C by direct method is most reliable and sensitive in CHD patients compare with FF, MFW, and ARF